These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32873702)

  • 81. Increased numbers of P63-positive/CD117-positive cells in advanced adenoid cystic carcinoma give a poorer prognosis.
    Zhou Q; Chang H; Zhang H; Han Y; Liu H
    Diagn Pathol; 2012 Sep; 7():119. PubMed ID: 22963430
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Angiogenesis markers in breast cancer--potentially useful tools for priority setting of anti-angiogenic agents.
    Keyhani E; Muhammadnejad A; Behjati F; Sirati F; Khodadadi F; Karimlou M; Moghaddam FA; Pazhoomand R
    Asian Pac J Cancer Prev; 2013; 14(12):7651-6. PubMed ID: 24460348
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Immunostaining of ∆Np63 (using the p40 antibody) is equal to that of p63 and CK5/6 in high-grade ductal carcinoma in situ of the breast.
    Sailer V; Lüders C; Kuhn W; Pelzer V; Kristiansen G
    Virchows Arch; 2015 Jul; 467(1):67-70. PubMed ID: 25850754
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.
    Yang M; Moriya T; Oguma M; De La Cruz C; Endoh M; Ishida T; Hirakawa H; Orita Y; Ohuchi N; Sasano H
    Pathol Int; 2003 Jul; 53(7):422-8. PubMed ID: 12828606
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Laminin 5 expression in metaplastic breast carcinomas.
    Carpenter PM; Wang-Rodriguez J; Chan OT; Wilczynski SP
    Am J Surg Pathol; 2008 Mar; 32(3):345-53. PubMed ID: 18300817
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Morphological features of basal-like subtype invasive carcinoma of breast].
    Gao LX; Yang GZ; Ding HY; Li L
    Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):83-7. PubMed ID: 18681317
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
    Carey LA; Berry DA; Cirrincione CT; Barry WT; Pitcher BN; Harris LN; Ollila DW; Krop IE; Henry NL; Weckstein DJ; Anders CK; Singh B; Hoadley KA; Iglesia M; Cheang MC; Perou CM; Winer EP; Hudis CA
    J Clin Oncol; 2016 Feb; 34(6):542-9. PubMed ID: 26527775
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray.
    Möllerström E; Kovács A; Lövgren K; Nemes S; Delle U; Danielsson A; Parris T; Brennan DJ; Jirström K; Karlsson P; Helou K
    BMC Cancer; 2010 Jun; 10():296. PubMed ID: 20553615
    [TBL] [Abstract][Full Text] [Related]  

  • 90. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.
    Silwal-Pandit L; Vollan HK; Chin SF; Rueda OM; McKinney S; Osako T; Quigley DA; Kristensen VN; Aparicio S; Børresen-Dale AL; Caldas C; Langerød A
    Clin Cancer Res; 2014 Jul; 20(13):3569-80. PubMed ID: 24803582
    [TBL] [Abstract][Full Text] [Related]  

  • 91. p40 (ΔNp63) expression in breast disease and its correlation with p63 immunohistochemistry.
    Kim SK; Jung WH; Koo JS
    Int J Clin Exp Pathol; 2014; 7(3):1032-41. PubMed ID: 24696720
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Aberrant p63 and WT-1 expression in myoepithelial cells of pregnancy-associated breast cancer: implications for tumor aggressiveness and invasiveness.
    Xu Z; Wang W; Deng CX; Man YG
    Int J Biol Sci; 2009; 5(1):82-96. PubMed ID: 19173015
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Metaplastic carcinoma of the breast: an immunohistochemical study.
    Altaf FJ; Mokhtar GA; Emam E; Bokhary RY; Mahfouz NB; Al Amoudi S; Al-Gaithy ZK
    Diagn Pathol; 2014 Jul; 9():139. PubMed ID: 25030022
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Clinicopathologic characteristics of pleomorphic carcinoma of the breast.
    Zhao J; Lang R; Guo X; Chen L; Gu F; Fan Y; Fu X; Fu L
    Virchows Arch; 2010 Jan; 456(1):31-7. PubMed ID: 20013346
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Molecular Profiling of the Metaplastic Spindle Cell Carcinoma of the Breast Reveals Potentially Targetable Biomarkers.
    Vranic S; Stafford P; Palazzo J; Skenderi F; Swensen J; Xiu J; Spetzler D; Gatalica Z
    Clin Breast Cancer; 2020 Aug; 20(4):326-331.e1. PubMed ID: 32197944
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer.
    Boyle DP; McArt DG; Irwin G; Wilhelm-Benartzi CS; Lioe TF; Sebastian E; McQuaid S; Hamilton PW; James JA; Mullan PB; Catherwood MA; Harkin DP; Salto-Tellez M
    Histopathology; 2014 Sep; 65(3):340-52. PubMed ID: 24612173
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The prognostic significance of p63 and Ki-67 expression in myoepithelial carcinoma.
    Jiang YH; Cheng B; Ge MH; Zhang G
    Head Neck Oncol; 2012 Mar; 4():9. PubMed ID: 22452794
    [TBL] [Abstract][Full Text] [Related]  

  • 98. p53 protein expression patterns associated with TP53 mutations in breast carcinoma.
    Anderson SA; Bartow BB; Harada S; Siegal GP; Wei S; Dal Zotto VL; Huang X
    Breast Cancer Res Treat; 2024 Aug; 207(1):213-222. PubMed ID: 38900212
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas.
    Cakir A; Gonul II; Uluoglu O
    Diagn Pathol; 2012 Oct; 7():145. PubMed ID: 23082819
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Primary squamous cell carcinoma of the breast with unusual basal-HER2 phenotype.
    Shui R; Li A; Yang F; Zhou X; Yu B; Xu X; Yang W
    Int J Clin Exp Pathol; 2014; 7(8):5203-9. PubMed ID: 25197398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.